Value Investing: 1 Biotech Stock With Huge Opportunity

Cardiol Therapeutics Inc. (TSX:CRDL) owns an intellectual property portfolio that has been built from in-house technology and strategic relationships with partners.

| More on:
sad concerned deep in thought

Image source: Getty Images

Cardiol Therapeutics (TSX:CRDL) is a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD).

The company recently received approval from the Food and Drug Administration (FDA) for the company’s investigational new drug (IND) application to commence a double-blind, placebo-controlled clinical trial investigating the efficacy and safety of Cardiol’s lead product, CardiolRx, in hospitalized COVID-19 patients with a prior history of CVD. CardiolRx is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced.

COVID-19, a disease caused by the SARS-CoV-2, is primarily a respiratory disease. However, an increasing number of reports indicate that COVID-19 patients are at higher risk of developing cardiovascular complications.

Robust product development

A recent study showed that 35% of hospitalized COVID-19 patients had underlying CVD. The company believes that the rationale for using cannabidiol to treat patients with COVID-19 who have a prior history of CVD is based on extensive pre-clinical investigations by Cardiol and others in models of cardiovascular inflammation. These studies have demonstrated that cannabidiol has impressive anti-inflammatory and anti-fibrotic activity and that it improves myocardial function in models of heart failure.

Cardiol is also planning to file an IND for a Phase II international trial of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The company is developing a subcutaneous formulation of CardiolRx for the treatment of inflammation in the heart that is associated with the development and progression of heart failure.

Wealth of experience

Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the United States alone exceeding $30 billion. In parallel with the clinical programs in inflammatory heart disease, Cardiol is also developing a commercial opportunity in the Canadian medical cannabinoid market through exclusive supply agreements.

Further, Cardiol brings together a wealth of research and development experience, advanced manufacturing capabilities, and an executive team with extensive industry experience and expertise in commercializing proprietary drugs. In 2020, Cardiol announced the commercial introduction of Cortalex, an extra-strength oral cannabidiol formulation. The product is available for purchase across North America.

Huge opportunity

Statistics Canada has indicated that the total medical cannabinoid market was almost $600 million annually in Canada as of 2020. Cardiol believes that a pure pharmaceutically produced cannabidiol product manufactured by a Health Canada-approved, FDA-registered, and inspected pharmaceutical facility will have key competitive advantages regarding consistency, safety, and purity.

Valuable intellectual property portfolio

Cardiol’s intellectual property portfolio has been built from in-house technology and product research and development, as well as strategic relationships with partners. Further, the company has a consistent licensing revenue stream through an exclusive in-licensing arrangement with Meros under which Cardiol licenses territorial rights to technologies, patents, and related know-how. Overall, the company owns some very valuable intangible assets.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

growing plant shoots on stacked coins

Got $5,000? 3 Stocks to Hold for the Next 20 Years

Given their high-growth potential and solid growth initiatives, these three stocks are excellent additions to your long-term portfolio.

Read more »

money cash dividends

TFSA Passive Income: Make $455/Month Tax Free for Life

Canadian investors can churn out big passive income in their TFSA with stocks like Freehold Royalties Ltd. (TSX:FRU) and others…

Read more »

Natural gas
Energy Stocks

Canadian Natural Resources Stock (TSX:CNQ): Profiting From Natural Gas Strength

Soaring cash flows and dividends have come to characterize Canadian Natural Resources stock as well as other natural gas stocks.

Read more »

Question marks in a pile

Uranium Stocks: Ready for a Breakout?

Uranium mining stocks like Cameco Corporation (TSX:CCO)(NYSE:CCJ) could be ready for a breakout.

Read more »

grow dividends
Dividend Stocks

1 Cheap Stock to Turn a $20,000 TFSA Into $267,000

If you're looking to boost your TFSA, you need a cheap stock that you can hold for decades. And I…

Read more »

Profit dial turned up to maximum

This Little-Known TSX Stock Has Huge Potential

From new technologies to unglamorous but promising service businesses, there are plenty of potentially explosive, little-known stocks trading on Canadian…

Read more »

Canadian Dollars
Stocks for Beginners

How a $10,000 TFSA or RRSP Investment Can Become $193,000

Are you looking to build wealth for retirement? Here's one way that turned a $10,000 TFSA or RRSP investment into…

Read more »

edit Person using calculator next to charts and graphs
Dividend Stocks

2 of the Best Monthly Passive-Income Stocks to Buy in Canada Right Now

Here are two of the best Canadian monthly passive income stocks you can consider buying right now to hold for…

Read more »